Zobrazeno 1 - 10 of 11 pro vyhledávání: '"Peter Gerondelis"'
1
Inhibition of the Ribonuclease H Activity of HIV-1 Reverse Transcriptase by GSK5750 Correlates with Slow Enzyme-Inhibitor Dissociation
Autor: Greg L. Beilhartz, Peter Gerondelis, Felix Deanda, Brian A. Johns, Marianne Ngure, Matthias Götte
Publikováno v: Journal of Biological Chemistry. 289:16270-16277
Compounds that efficiently inhibit the ribonuclease (RNase) H activity of the human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) have yet to be developed. Here, we demonstrate that GSK5750, a 1-hydroxy-pyridopyrimidinone analog, b
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::700f961467c7bda2583a69220caa2cfd
https://doi.org/10.1074/jbc.m114.569707
Zobrazit plný text záznamu
2
Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir
Autor: Joseph Horton, Belinda Ha, Lisa L. Ross, Richard Elion, E. R. Lanier, C. Cohen, Peter Gerondelis, E. Rouse, Edwin DeJesus
Publikováno v: Journal of Antimicrobial Chemotherapy
Background HIV clonal genotypic analysis (CG) was used to investigate whether a more sensitive analysis method would detect additional low-abundance mutations compared with population genotyping (PG) in antiretroviral-naive patients who experienced v
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36e86fe8dc69e8a4e9a1e43f4637160a
https://doi.org/10.1093/jac/dkp419
Zobrazit plný text záznamu
3
Pyridopyrimidinone inhibitors of HIV-1 RNase H
Autor: Brian A. Johns, Emile Johann Velthuisen, Kendra E. Hightower, John W. Seal, Peter Gerondelis, Kevin K. Brown, Ming Li, Lisa A. Leesnitzer, Wenwen Zhang, Yan Chen, Sonia R. Miranda, Ke Mou
Publikováno v: European journal of medicinal chemistry. 83
Using a structure based pharmacophore design, a weak inhibitor of RNase H, identified from a small library of two metal binding HIV-1 integrase inhibitors, was optimized for potency and physicochemical properties. This manuscript describes the SAR an
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bd973f72221ddfffa959c04284f6b71
https://pubmed.ncbi.nlm.nih.gov/24997293
Zobrazit plný text záznamu
4
Mutants of Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase Resistant to Nonnucleoside Reverse Transcriptase Inhibitors Demonstrate Altered Rates of RNase H Cleavage That Correlate with HIV-1 Replication Fitness in Cell Culture
Autor: Amanda Lloyd, Richard H. Archer, Carrie Dykes, Robert A. Bambara, Philip J. Fay, Richard C. Reichman, Lisa M. Demeter, Peter Gerondelis
Publikováno v: Journal of Virology. 74:8390-8401
Three mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (V106A, V179D, and Y181C), which occur in clinical isolates and confer resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs), were analyzed for RNA- an
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2260d42dcdfecef7e8255504e55a6b8
https://doi.org/10.1128/jvi.74.18.8390-8401.2000
Zobrazit plný text záznamu
5
The P236L Delavirdine-Resistant Human Immunodeficiency Virus Type 1 Mutant Is Replication Defective and Demonstrates Alterations in both RNA 5′-End- and DNA 3′-End-Directed RNase H Activities
Autor: Richard H. Archer, Richard C. Reichman, Robert A. Bambara, Chockalingam Palaniappan, Philip J. Fay, Peter Gerondelis, Lisa M. Demeter
Publikováno v: Journal of Virology. 73:5803-5813
Major advances have been made recently in the therapy of human immunodeficiency virus type 1 (HIV-1) infection, which is estimated to affect more than 30 million people worldwide (54). Currently recommended combination antiretroviral regimens contain
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c708eb541184963d39ecb1abcfcafe70
https://doi.org/10.1128/jvi.73.7.5803-5813.1999
Zobrazit plný text záznamu
7
Sensitivity of phenotypic susceptibility analyses for nonthymidine nucleoside analogues conferred by K65R or M184V in mixtures with wild-type HIV-1
Autor: Lan Trinh, Elizabeth Rouse, Neil Parkin, Mark R. Underwood, Marty St. Clair, Peter Gerondelis, Lisa L. Ross, David M. Irlbeck, E. Randall Lanier
Publikováno v: The Journal of infectious diseases. 199(1)
Thymidine-sparing triple-nucleoside regimens have exhibited poor virologic response despite apparent phenotypic susceptibility to 2 of 3 regimen components at early time points. Phenotypic resistance masking by wild-type virus may explain this discre
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0456aa6d462958e5909f8912dd990d1
https://pubmed.ncbi.nlm.nih.gov/19032103
Zobrazit plný text záznamu
8
Differential impact of thymidine analogue mutations on emtricitabine and lamivudine susceptibility
Autor: Lisa L. Ross, Mark R. Underwood, Colombe Chappey, Neil Parkin, Peter Gerondelis, Ernest R Lanier, Marty St. Clair
Publikováno v: Journal of acquired immune deficiency syndromes (1999). 43(5)
The impact of drug resistance-associated mutations on subsequent antiretroviral therapy is an important consideration in managing treatment-experienced, HIV-1-infected patients. Lamivudine (3TC) and emtricitabine (FTC) are structurally related nucleo
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5ce231c992418337a47a1d3b8fa4e4e
https://pubmed.ncbi.nlm.nih.gov/17075395
Zobrazit plný text záznamu
9
HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine
Autor: Steve R. Cox, L. Berrios, Richard C. Reichman, Lisa M. Demeter, William W. Freimuth, A. Dexter, Patricia M. Meehan, Peter Gerondelis, Gene D. Morse
Publikováno v: Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association. 14(2)
Previous studies have shown that the human immunodeficiency virus type 1 (HIV-1) reverse transcriptase mutation Y181C, which confers high-level resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs), develops rarely during therapy with
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::289b10214f8a7e8e9189ed2e77385919
https://pubmed.ncbi.nlm.nih.gov/9052722
Zobrazit plný text záznamu
10
Development of zidovudine resistance mutations in patients receiving prolonged didanosine monotherapy
Autor: Richard C. Reichman, Raphael Dolin, Angela Dexter, Peter Gerondelis, Lisa M. Demeter, Taimor Nawaz, Gene D. Morse
Publikováno v: The Journal of infectious diseases. 172(6)
Human immunodeficiency virus type 1 (HIV-1) isolates from 2 patients who received didanosine (ddI) monotherapy for > 2 years were analyzed for reverse transcriptase (RT) mutations by sequencing of proviral DNA from peripheral blood mononuclear cell c
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ae80ba3b5939a2b80b9265c568b443c
https://pubmed.ncbi.nlm.nih.gov/8699089
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje